London, UK, 16 July 2007, Curidium Medica plc, (LSE:CUR.L - News), the personalized medicine company focused on bringing the right drug to the right patient, today announced that it has filed worldwide trademark applications for PsychINDxTM as the name for its diagnostic test to classify patients with schizophrenia/bipolar disorder into four subgroups. The development of the test was announced previously by the Company. Curidium believes that PsychINDxTM may have the potential to improve the treatment of schizophrenic/bipolar disorder patients and may support the development of new drug treatments targeted for the different schizophrenia/bipolar disorder patient subgroups.
